NHS Launches Rapid Genomic Test Pilot to Diagnose Brain Tumours in Two Hours

England's National Health Service has launched a major clinical pilot of a rapid genomic test designed to deliver definitive brain tumour classifications within hours instead of the weeks required by conventional pathology. The initiative, backed by a £2 million investment over two years into the Brain Cancer NHS Genomic Network of Excellence, aims to accelerate targeted treatments and intraoperative surgical decisions for thousands of patients annually.

According to My Patient Advice / Cancer Research UK data, for Cancer Research UK, Lifetime risk for brain and other CNS tumours is approximately 1 in 66 for UK females and 1 in 74 for UK males, with one-quarter of all new cases occurring in adults aged 75 and over.

According to Neuro-Oncology Practice / Oxford University Press / NIH, for Tessa Jowell Standards of Excellence, The benchmark standard for integrated molecular neuropathology diagnosis is 14 to 28 days, whereas real-world hospital turnaround times average 21 days for integrated reports and 58 days for whole genome sequencing.

According to The Brain Tumour Charity, around 13,000 people in the UK are diagnosed with a primary brain tumour each year, representing the single biggest cancer killer of children and adults under 40. According to East Genomics / NHS England, for Steve Palmer, Rapid molecular diagnosis eliminates weeks of severe anxiety for patients and allows immediate implementation of postoperative oncological treatment plans.

The diagnostic technology sequences the genetic code of small tumour tissue extracted during biopsy or open procedures. While conventional workflows rely on microscopic pathology evaluations that can take up several weeks, the pilot workflow completed DNA sequencing in approximately 20 minutes during a live operation at Nottingham University Hospitals, feeding initial classifications back to the surgical team in under two hours.

Intraoperative Guidance and Clinical Decision-Making

Receiving genetic data while a resection is underway provides operating surgeons with actionable intelligence to determine tumour boundaries. According to Stuart Smith, Consultant Neurosurgeon at Nottingham University Hospitals NHS Trust and Clinical Associate Professor at the University of Nottingham, having detailed genetic insights during surgery is transformative. Smith noted that this information helps surgical teams judge how far they can safely resect tissue while protecting surrounding healthy brain structures.

Beyond surgical navigation, rapid genetic profiling enables faster access to targeted therapies such as chemotherapy and radiotherapy. Because certain clinical trials require exact molecular markers before patient enrollment, expedited turnaround times prevent delays in accessing experimental protocols. Professor Frankie Swords, NHS medical director, stated that the technology addresses the agonizing wait families face while removing uncertainties during early treatment phases.

National Rollout and Phased Implementation

The pilot program is initially rolling out across five specialist centres in England, building upon preliminary work conducted in Nottingham and Birmingham. The first phase incorporates University Hospitals Birmingham NHS Foundation Trust, Nottingham University Hospitals NHS Trust, Great Ormond Street Hospital for Children NHS Foundation Trust, King's College Hospital NHS Foundation Trust, and Newcastle Hospitals NHS Foundation Trust.

A second implementation phase will expand the network to laboratories in Bristol, Oxford, Leeds, and Manchester. Health and Social Care Secretary Yvette Cooper described the initiative as a major milestone for the domestic life sciences sector, emphasizing that routine deployment positions patients at the forefront of global oncology innovations. According to East Genomics / NHS England, professor Dame Sue Hill, Chief Scientific Officer for England, confirmed that the overarching objective is to gather robust operational evidence to transition rapid genomic screening into standard NHS care across all regions.